Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 22, 2021 - Issue 16: Pharmacotherapy for Diabetes and its complications
Submit an article Journal homepage
868
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Bexagliflozin for type 2 diabetes: an overview of the data

Omar Azzama Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, Royal Perth Hospital Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, Australia;b Department of Medicine, Royal Perth Hospital, Perth, Western Australia, AustraliaORCID Iconhttps://orcid.org/0000-0003-1790-2062View further author information
ORCID Icon,
Revathy Carnagarina Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, Royal Perth Hospital Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, AustraliaView further author information
,
Leslie Marisol Lugo-Gavidiaa Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, Royal Perth Hospital Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, AustraliaView further author information
,
Janis Noldea Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, Royal Perth Hospital Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, AustraliaView further author information
,
Vance B. Matthewsa Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, Royal Perth Hospital Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, AustraliaView further author information
&
Markus P. Schlaicha Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit, Royal Perth Hospital Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, Australia;c Departments of Cardiology and Nephrology, Royal Perth Hospital, Perth, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1765-0195View further author information
ORCID Icon
Pages 2095-2103 | Received 17 May 2021, Accepted 21 Jul 2021, Published online: 29 Jul 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Shubham Batra, Prabhjeet Kaur Bamrah & Manjusha Choudhary. (2023) Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds. Egyptian Journal of Basic and Applied Sciences 10:1, pages 69-82.
Read now

Articles from other publishers (4)

Eric Pasqualotto, Janine Midori Figueiredo Watanabe, Douglas Mesadri Gewehr, Raphaela da Silva Maintinguer, Simone van de Sande‐Lee, Gustavo Neves de Araujo, Fidel Silveira Leal & Carlos Eduardo Andrade Pinheiro. (2023) Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 25:7, pages 1794-1802.
Crossref
Jonali Ramani, Harshil Shah, Vivek K. Vyas & Manmohan Sharma. (2022) A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 6, pages 100074.
Crossref
Sandra Feijóo-Bandín, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, José Ramón González-Juanatey & Francisca Lago. (2022) Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. International Journal of Molecular Sciences 23:10, pages 5634.
Crossref
Lakshini Y. Herat, Jennifer Matthews, Omar Azzam, Markus P. Schlaich & Vance B. Matthews. (2022) Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Current Hypertension Reports 24:3, pages 67-74.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.